Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Arlocabtagene Autoleucel
Multiple Myeloma
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for Arlocabtagene Autoleucel in Multiple Myeloma are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06297226: Phase 2 trial, sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, drug Arlocabtagene Autoleucel. Primary completion date 2027-06-30 (estimated).”